Roche Holding AG (ROG), the world’s largest maker of cancer drugs, looks forward to the “swift completion” of its takeover offer for Illumina Inc. (ILMN:US), a spokesman said.
“We look forward to the possibility of a swift completion of the Illumina transaction that offers immediate value to Illumina’s shareholders,” Alexander Klauser, a spokesman for the Basel, Switzerland-based drugmaker, said in an e-mailed statement today.
He commented after SonntagsZeitung reported that Roche may drop the hostile bid, which values the San Diego-based gene- sequencing company at about $6.7 billion. The newspaper cited an unidentified person close to Roche’s board.
The Swiss drugmaker on March 29 raised its offer for Illumina by 15 percent to $51 a share. Investors have until April 20 at 6 p.m. New York time to tender their stock. Illumina’s technology may help Roche tailor medicines to individual patients.
To contact the reporter on this story: Trista Kelley in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org